Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4942)
All Articles published online
|
Nov 14, 2011 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Guslandi M. Rifaximin in the treatment of inflammatory bowel disease. World J Gastroenterol 2011; 17(42): 4643-4646 [PMID: 22180705 DOI: 10.3748/wjg.v17.i42.4643] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v17/i42/4643.htm |
| Number | Citing Articles |
| 1 |
Christopher J Damman, Samuel I Miller, Christina M Surawicz, Timothy L Zisman. The Microbiome and Inflammatory Bowel Disease: Is There a Therapeutic Role for Fecal Microbiota Transplantation?. American Journal of Gastroenterology 2012; 107(10): 1452 doi: 10.1038/ajg.2012.93
|
| 2 |
Serena Bertoni, Zehua Liu, Alexandra Correia, João Pedro Martins, Antti Rahikkala, Flavia Fontana, Marianna Kemell, Dongfei Liu, Beatrice Albertini, Nadia Passerini, Wei Li, Hélder A. Santos. pH and Reactive Oxygen Species‐Sequential Responsive Nano‐in‐Micro Composite for Targeted Therapy of Inflammatory Bowel Disease. Advanced Functional Materials 2018; 28(50) doi: 10.1002/adfm.201806175
|
| 3 |
Karin Fetter, Markus Weigel, Benjamin Ott, Moritz Fritzenwanker, Sebastian Stricker, Jan de Laffolie, Torsten Hain. The microbiome landscape in pediatric Crohn’s disease and therapeutic implications. Gut Microbes 2023; 15(2) doi: 10.1080/19490976.2023.2247019
|
| 4 |
Donatella Comito, Antonio Cascio, Claudio Romano. Microbiota biodiversity in inflammatory bowel disease. Italian Journal of Pediatrics 2014; 40(1) doi: 10.1186/1824-7288-40-32
|
| 5 |
Masayoshi Sato, Kazuyuki Fujii, Hiroko Takagi, Isao Shibuya, Daisuke Oka, Naomitsu Yamaya, Hiraku Hagita, Makoto Matsumoto, Katsuya Inagaki. Antibacterial and Immunosuppressive Effects of OPS-2071, a Candidate Therapy for Inflammatory Bowel Disease. Digestive Diseases and Sciences 2022; 67(8): 3993 doi: 10.1007/s10620-021-07237-2
|
| 6 |
Herbert L. DuPont, Graeme N. Forrest. The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review. Clinical Microbiology Reviews 2023; 36(4) doi: 10.1128/cmr.00039-23
|
| 7 |
Taha Rashid, Alan Ebringer, Clyde Wilson. The Role ofKlebsiellain Crohn’s Disease with a Potential for the Use of Antimicrobial Measures. International Journal of Rheumatology 2013; 2013: 1 doi: 10.1155/2013/610393
|
| 8 |
G. Adrienne Weiss, Thierry Hennet. Mechanisms and consequences of intestinal dysbiosis. Cellular and Molecular Life Sciences 2017; 74(16): 2959 doi: 10.1007/s00018-017-2509-x
|
| 9 |
Jie Wen Su, Jing Jing Ma, Hong Jie Zhang. Use of antibiotics in patients with Crohn's disease: A systematic review and meta‐analysis. Journal of Digestive Diseases 2015; 16(2): 58 doi: 10.1111/1751-2980.12216
|
| 10 |
Hanze Guo, Yan Chi, Naiyu Chi. Bioinformatis analysis reveals possible molecular mechanism of PXR on regulating ulcerative colitis. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-83742-8
|
| 11 |
Mi-Sung Kim, Walter Morales, Andres Ardila Hani, Sharon Kim, Gene Kim, Stacy Weitsman, Christopher Chang, Mark Pimentel. The Effect of Rifaximin on Gut Flora and Staphylococcus Resistance. Digestive Diseases and Sciences 2013; 58(6): 1676 doi: 10.1007/s10620-013-2675-0
|
| 12 |
Ivan Kushkevych, Josef Jampílek. Probiotics in the Prevention and Management of Human Diseases. 2022; : 59 doi: 10.1016/B978-0-12-823733-5.00016-7
|
| 13 |
Sabine Becker, Louise B. Grode, Ole K. Bonderup. Rifaximin Treatment of Collagenous Colitis: A Randomised, Double-Blind, Placebo-Controlled Trial. Inflammatory Intestinal Diseases 2024; 9(1): 22 doi: 10.1159/000536124
|
| 14 |
Loris R. Lopetuso, Marco Napoli, Gianenrico Rizzatti, Antonio Gasbarrini. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease. Expert Opinion on Investigational Drugs 2018; 27(6): 543 doi: 10.1080/13543784.2018.1483333
|
| 15 |
Cristina Tocia, Irina Magdalena Dumitru, Luana Alexandrescu, Lucian Cristian Petcu, Eugen Dumitru. Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?. Medicine 2021; 100(1): e24059 doi: 10.1097/MD.0000000000024059
|
| 16 |
Francesca Romana Ponziani, Viviana Gerardi, Silvia Pecere, Francesca D’Aversa, Loris Lopetuso, Maria Assunta Zocco, Maurizio Pompili, Antonio Gasbarrini. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World Journal of Gastroenterology 2015; 21(43): 12322-12333 doi: 10.3748/wjg.v21.i43.12322
|
| 17 |
David M. Rothstein. Rifamycins, Alone and in Combination. Cold Spring Harbor Perspectives in Medicine 2016; 6(7): a027011 doi: 10.1101/cshperspect.a027011
|
| 18 |
Danilo Pagliari, Giovanni Gambassi, Ciriaco A. Piccirillo, Rossella Cianci. The Intricate Link among Gut “Immunological Niche,” Microbiota, and Xenobiotics in Intestinal Pathology. Mediators of Inflammation 2017; 2017: 1 doi: 10.1155/2017/8390595
|
| 19 |
Yu Jin, Xiaoyang Ren, Gangping Li, Ying Li, Lei Zhang, Huan Wang, Wei Qian, Xiaohua Hou. Beneficial effects of Rifaximin in post‐infectious irritable bowel syndrome mouse model beyond gut microbiota. Journal of Gastroenterology and Hepatology 2018; 33(2): 443 doi: 10.1111/jgh.13841
|
| 20 |
Stephen M. Vindigni, Timothy L. Zisman, David L. Suskind, Christopher J. Damman. The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Therapeutic Advances in Gastroenterology 2016; 9(4): 606 doi: 10.1177/1756283X16644242
|
| 21 |
Artur Dembiński, Zygmunt Warzecha, Piotr Ceranowicz, Marcin Dembiński, Jakub Cieszkowski, Tomasz Gosiewski, Małgorzata Bulanda, Beata Kuśnierz-Cabala, Krystyna Gałązka, Peter Christopher Konturek. Synergic Interaction of Rifaximin and Mutaflor (Escherichia coliNissle 1917) in the Treatment of Acetic Acid-Induced Colitis in Rats. Gastroenterology Research and Practice 2016; 2016: 1 doi: 10.1155/2016/3126280
|
| 22 |
Nicole Parrish, Aravinda Vadlamudi, Neil Goldberg. Anaerobic adaptation of Mycobacterium avium subspecies paratuberculosis in vitro: similarities to M. tuberculosis and differential susceptibility to antibiotics. Gut Pathogens 2017; 9(1) doi: 10.1186/s13099-017-0183-z
|
| 23 |
Morgan E. Roberts, Jennifer L. Bishop, Xueling Fan, Jennifer L. Beer, Winnie W. S. Kum, Danielle L. Krebs, Morris Huang, Navkiran Gill, John J. Priatel, B. Brett Finlay, Kenneth W. Harder. Lyn Deficiency Leads to Increased Microbiota-Dependent Intestinal Inflammation and Susceptibility to Enteric Pathogens. The Journal of Immunology 2014; 193(10): 5249 doi: 10.4049/jimmunol.1302832
|
| 24 |
Orna Nitzan, Mazen Elias, Avi Peretz, Walid Saliba. Role of antibiotics for treatment of inflammatory bowel disease. World Journal of Gastroenterology 2016; 22(3): 1078-1087 doi: 10.3748/wjg.v22.i3.1078
|
| 25 |
Bao‐Jian Guo, Zhao‐Xiang Bian, Hong‐Cong Qiu, Yi‐Tao Wang, Ying Wang. Biological and clinical implications of herbal medicine and natural products for the treatment of inflammatory bowel disease. Annals of the New York Academy of Sciences 2017; 1401(1): 37 doi: 10.1111/nyas.13414
|
| 26 |
Giovanni Cammarota, Gianluca Ianiro, Rossella Cianci, Stefano Bibbò, Antonio Gasbarrini, Diego Currò. The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy. Pharmacology & Therapeutics 2015; 149: 191 doi: 10.1016/j.pharmthera.2014.12.006
|
| 27 |
Vishesh Kothary, Ellen J. Scherl, Brian Bosworth, Zhi-Dong Jiang, Herbert L. DuPont, Josee Harel, Kenneth W. Simpson, Belgin Dogan.
Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in
rpoB
, and Activity of Phe-Arg-β-Naphthylamide-Inhibitable Efflux Pumps
. Antimicrobial Agents and Chemotherapy 2013; 57(2): 811 doi: 10.1128/AAC.02163-12
|
| 28 |
Beatrice Campanella, Massimo Onor, Tommaso Lomonaco, Edoardo Benedetti, Emilia Bramanti. HS-SPME-GC-MS approach for the analysis of volatile salivary metabolites and application in a case study for the indirect assessment of gut microbiota. Analytical and Bioanalytical Chemistry 2019; 411(28): 7551 doi: 10.1007/s00216-019-02158-6
|
| 29 |
Caroline Schrodt, Erin E. McHugh, Mary Ann Gawinowicz, Herbert L. DuPont, Eric L. Brown, Hendrik W. van Veen. Rifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis. PLoS ONE 2013; 8(7): e68550 doi: 10.1371/journal.pone.0068550
|
| 30 |
M. Pimentel. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Alimentary Pharmacology & Therapeutics 2016; 43(S1): 37 doi: 10.1111/apt.13437
|
| 31 |
Melanie Jane Maslow, Cynthia Portal-Celhay. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 2015; : 339 doi: 10.1016/B978-1-4557-4801-3.00027-8
|
| 32 |
Roman Kotłowski. Use of Escherichia coli Nissle 1917 producing recombinant colicins for treatment of IBD patients. Medical Hypotheses 2016; 93: 8 doi: 10.1016/j.mehy.2016.05.002
|
| 33 |
Adam D. Farmer, Holly A. Randall, Qasim Aziz. It's a gut feeling: How the gut microbiota affects the state of mind. The Journal of Physiology 2014; 592(14): 2981 doi: 10.1113/jphysiol.2013.270389
|
| 34 |
Annalisa Ricci, Erika Coppo, Ramona Barbieri, Eugenio A. Debbia, Anna Marchese. The effect of sub-inhibitory concentrations of rifaximin on urease production and on other virulence factors expressed by Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus. Journal of Chemotherapy 2017; 29(2): 67 doi: 10.1080/1120009X.2016.1195069
|